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CONCLUSIONS: Retrospective database analysis has yielded a
previously unavailable resource allocation and cost structure that
illuminates our understanding of severe sepsis management 
economics.
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OBJECTIVE: Although treatment failure can substantially
increase medical-care costs, data on the economic impact of
treatment failure in acute bacterial maxillary sinusitis (ABMS)
are lacking. The absence of these data undermines efforts to
incorporate pharmacoeconomic criteria in clinical decision-
making (beyond simplistic comparisons of the acquisition costs
of competing antibiotics). We conducted this study to document
the cost of treatment failure in ABMS. METHODS: Data were
obtained from a prospective, randomized, double-blind, equiva-
lency study in which adults with radiographic evidence of ABMS
were randomized to treatment with telithromycin 800mg once
a day for 5 days followed by placebo for 5 days (n = 159) or
moxiﬂoxacin 400mg once a day for ten days (n = 163). Patients
were asked to record in a study diary all nonprotocol sinusitis-
related health-care utilization over a 30-day follow-up period,
including outpatient visits, tests and procedures, prescription
medications, and over-the-counter remedies. Unit costs were
assigned to all measures of health-care utilization using nation-
ally representative published sources. All utilization and cost
measures were analyzed irrespective of treatment assignment and
compared between patients who were treatment “successes”
versus “failures”, as assessed for the primary efﬁcacy endpoint.
RESULTS: A total of 253 subjects were declared treatment suc-
cesses and 47 treatment failures. Treatment failures incurred
sinusitis-related medical-care costs that were nearly sixfold
higher than treatment successes ($126.11 vs $21.98; p < 0.001),
reﬂecting higher mean utilization of unscheduled outpatient ser-
vices (0.40 vs 0.10 visits; p = 0.009), tests and procedures (0.32
vs 0.08; p = 0.002), and nonstudy prescription medications (1.23
vs 0.39; p < 0.001). Use of over-the-counter drugs did not differ
signiﬁcantly (0.68 vs. 0.54 units purchased; p = 0.763). CON-
CLUSIONS: The cost of treatment failure in ABMS appears to
be substantial. Clinical decision-making regarding choice of
antibiotic therapy in ABMS should involve consideration of how
treatment failure might increase overall costs of sinusitis-related
care.
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OBJECTIVE: This study evaluates the cost-effectiveness of four
antimicrobial regimens (e.g., levoﬂoxacin monotherapy, ceftri-
axone monotherapy, ceftriaxone plus a macrolide, and ceftriax-
one plus levoﬂoxacin) for the treatment of patients admitted to
the medical ﬂoor with class IV or V community-acquired pneu-
monia (CAP). METHODS: All adult patients with a principal
discharge diagnosis of pneumonia, admitted to Baptist-Health
System from November 1, 1999 to April 30, 2000 were evalu-
ated. Medical ﬂoor patients who met criteria for Pneumonia
Severity Index (PSI) risk class IV or V were included in this analy-
sis. Total hospital charges were converted to costs using the 
hospital cost-to-charge ratio. Wilcoxon Rank Sum was used to
evaluate associations between antimicrobials received (indepen-
dent variable) and total hospital cost (dependent variable). Cost-
effectiveness ratios were determined by dividing the total
hospital cost by the percent survival. RESULTS: A total of 649
patients were managed on the medical ﬂoor with 415 (64%)
meeting the criteria for PSI risk class IV (N = 274) or V (N =
141) CAP. Costs (median, 25th and 75th quartile) were as
follows: total hospital cost ($4087 [$2590–$6554]), pharmacy
costs ($606 [$366–$1092]), and antibiotic costs ($112
[$66–$184]). Total hospital costs were lowest for levoﬂoxacin
monotherapy (N = 151, $3506 [$2231–$5870]), followed by 
ceftriaxone monotherapy (N = 61, $3758 [$2741–$6071]), 
ceftriaxone plus a macrolide (N = 61, $4163 [$3100–$5726]),
and ceftriaxone plus levoﬂoxacin (N = 38, $4830
[$2934–$7393]) (P = 0.0921). Survival was the highest for
patients who received ceftriaxone plus a macrolide (98%), fol-
lowed by ceftriaxone plus levoﬂoxacin (95%), levoﬂoxacin
monotherapy (94%), and ceftriaxone monotherapy (87%) 
(P = 0.0734). The most favorable cost-effectiveness ratio was
observed for patients who received levoﬂoxacin monotherapy
($3730 per expected cure), followed by ceftriaxone plus a
macrolide ($4248), ceftriaxone monotherapy ($4370), and cef-
triaxone plus levoﬂoxacin ($5367). CONCLUSION: Among
patients admitted to the medical ﬂoor for class IV or V CAP, lev-
oﬂoxacin monotherapy is the most cost-effective antimicrobial
regimen.
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OBJECTIVES: To present pharmacoeconomic evidence support-
ing the relative cost-effectiveness of two pegylated interferon
therapies, compared with the standard interferon and ribavirin
therapy, for hepatitis C treatment. METHODS: Evidence-based
decision analysis based on genotypes, treatment dose and dura-
tion, comparing the pharmacoeconomic beneﬁts of PEGASYS +
COPEGUS (peginterferon alfa-2a + ribavirin) versus REBE-
TRON (interferon alfa-2b + ribavirin) and PEG-Intron +
REBETOL (peginterferon alfa-2a + ribavirin) versus REBE-
TRON. Cost effectiveness is calculated in terms of the cost per
sustained virological response (SVR); timeframe includes the
course of therapy and treatment-free follow-up of 24-weeks. The
model adopts a managed care perspective and includes only
direct costs. Each therapy efﬁcacy rates, total costs, costs asso-
ciated with diagnosis, medical treatment, drug acquisition and
adverse events are calculated for base-case scenario and sensi-
tivity analyses. RESULTS: Drugs accounted for the largest
portion of total costs, followed by adverse events, diagnostic pro-
cedures and medical treatment. The total costs associated with
PEG-Intron+REBETOL ($29,510) compared with REBETRON
($25,864) imply an incremental cost-effectiveness ratio (ICER)
for PEG-Intron+REBETOL versus REBETRON of $60,767.
PEGASYS + COPEGUS provide an increased probability of
treatment success at a lower cost than REBETRON. Compared
with REBETRON, the combination of PEGASYS + COPEGUS
is deemed a dominant strategy. The results of the sensitivity
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analysis indicate that the results of the model are robust to
changes in the base case parameters and the ICERs for PEGASYS
+ COPEGUS versus REBETRON are consistently lower than the
ICERs of PEG-Intron + REBETOL versus REBETRON. CON-
CLUSIONS: The pegylated interferons provide a cost-effective,
if not cost-savings alternative to standard interferon + ribavirin.
In addition to the direct cost savings, PEGASYS + COPEGUS
dominate REBETRON with better efﬁcacy at a lower cost. The
model presented in this study is a critical tool to aid decision-
making for therapies that have the potential to improve public
health in large populations.
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OBJECTIVES: This study was conducted to examine character-
istics of patients with tinea capitis (TC) and project national
direct treatment costs in patients with TC from a third-party
payers’ perspective. METHODS: This retrospective cohort study
is based on the MarketScan® research database during January
1, 1999 to December 31, 2002. Study patients were identiﬁed if
they had a diagnosis for TC (ICD-9 code: 110) and had contin-
uous medical and prescription coverage. Direct treatment costs
included costs associated with physician ofﬁce visits, hospital-
izations, and prescription drugs, calculated from the third-party
payers’ perspective after adjusting to 2002 US dollar values. The
parametric mean was calculated because treatment costs were
observed to be skewed. Appropriate distribution of treatment
costs was selected based on testing with mixed exponential,
mixed weibull, and mixed log-normal distribution. The nation-
wide direct treatment costs attributable to TC were projected
based on the U.S. privately insured population. RESULTS: In
2001, 2791 diagnosed patients with TC were identiﬁed of whom
60% were new (incidence cases) and 40% were recurrent. TC
was more prevalent in children under 16 years old (62%), among
males (59%), and those in the southern region (64%) of the U.S.
The average annual cost per patient was $224 (parametric mean:
$220), which was comprised of costs for prescription drugs
(63%), outpatient visits (36%), and hospitalizations (1%). Costs
for an oral antifungal accounted for 43% of prescription costs
and topical antifungal for 11%. Average costs for patients <3
years old were half of those for patients >50 years old ($185 vs.
$351). The national direct treatment costs attributable to TC
were estimated to be $42,948,362 in US privately insured
employees. CONCLUSION: This study demonstrates that
patients with TC consume a substantial amount of health care
resources from the perspective of the third party payers.
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OBJECTIVE: to estimate the cost-effectiveness of peginterferon
alfa-2a 180mcg weekly and ribavirin 1000mg/d (PegIFN2a + R)
relative to peginterferon alfa-2b 1.5mcg/kg weekly and ribavirin
800mg/d (PegIFN2b + R) in chronic hepatitis C patients without
preexisting cirrhosis. METHODS: A Markov model was devel-
oped to project lifelong clinical and economic outcomes in 45
year-old patients based on published in literature transition prob-
abilities and utility values and Polish data on health care resource
utilisation and unit cost. As no clinical trials comparing directly
the analysed medications are available, there was used the
method of indirect comparison by the common reference such as
IFN2b + R. The duration of treatment was 48 weeks and 24
weeks respectively in patients with HCVgenotype-1 (group I)
and non-1 (group II). Predictability test was performed after 12
weeks and 24 weeks in those receiving PegIFN2a + R and
PegIFN2b + R respectively. Effectiveness was expressed in LY
and QALY. Only direct medical costs were analysed from health-
care payer’s perspective. Simple one-way sensitivity analyses of
the base case were performed. RESULTS: In group I PegIFN2a
+ R in comparison to PegIFN2b + R showed the same effective-
ness (29.4 LY, 12.8 QALY) and lower cost (103,697 vs. 114,469
PLN/patient, 1EUR = 4.5 PLN in 2003). In group II PegIFN2a
+ R relative to PegIFN2b + R increased life expectancy by 1.17
LY or 0.69 QALY and reduced the costs by 23,322 PLN per
patient. The main cost drivers were the cost of analysed PegIFNs,
regardless of HCV genotype. The sensitivity analysis indicated
that the results were sensitive to the rate of sustained virological
response. CONCLUSION: The results suggest, that within a
Polish context PegIFN2a + R in comparison to PegIFN2b + R
appears to be cost-saving treatment option in HCVgenotype-1
infected patients and dominant therapy in HCVgenotype non-1
infected patients.
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OBJECTIVES: Recent data suggest that fungal foot infections
along with other risk factors are predisposing conditions for bac-
terial cellulitis and erysipelas of the leg (BCERL). However, there
is limited information available on the number of cases of bac-
terial cellulitis and erysipelas of the leg and related treatment
costs. The purpose of this study was to assess the burden of
illness of BCERL in The Netherlands in 2001. METHODS: Data
for this study were obtained from different linked databases: 
hospital information was obtained from the Dutch Medical 
Registry for ICD-9-CM codes 628.6 (bacterial cellulitis) and 035
(erysipelas), including all Dutch citizens. Those patients not
admitted to the hospital were estimated using general practi-
tioner data (65.000 residents). These data were extrapolated
using age/gender and disease speciﬁc standardisation. The same
sample was used to assess the localisation of the infection. For
all resources reimbursement costs were available. RESULTS: In
2001, approximately 30,000 patients (195 per 100.000 inhabi-
tants) have suffered from BCERL. Twenty-ﬁve hundred patients
of these patients were admitted to the hospital with an average
length of hospital stay of 12.1 days. The average costs per hos-
pitalisation for BCERL were $6700; total costs for The Nether-
lands were $17.1 million. Consultation costs were the second
most important contribution to the total costs; $3.5 million. The
contribution of prescription drugs to the total costs was limited;
0.1 million€ for the hospitalised patients and $0.9 million for the
outpatients. CONCLUSIONS: BCERL infections are common
and serious infections in The Netherlands. Hospitalisation only
occurs in less than 10% of the patients but contributes more than
80% to the total costs that cumulate up to $21 million a year.
Fungal foot infections along with other risk factors have been
identiﬁed as predisposing conditions for BCERL. Screening and
treatment of patients presenting such risk factors may help
reduce the economic burden of BCERL.
